KR20000052796A - 뉴트로킨 알파 - Google Patents

뉴트로킨 알파 Download PDF

Info

Publication number
KR20000052796A
KR20000052796A KR1019990703614A KR19997003614A KR20000052796A KR 20000052796 A KR20000052796 A KR 20000052796A KR 1019990703614 A KR1019990703614 A KR 1019990703614A KR 19997003614 A KR19997003614 A KR 19997003614A KR 20000052796 A KR20000052796 A KR 20000052796A
Authority
KR
South Korea
Prior art keywords
neutrokine
polypeptide
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019990703614A
Other languages
English (en)
Korean (ko)
Inventor
유구오-리앙
에브너라인하르트
니지안
Original Assignee
벤슨 로버트 에이치.
휴먼 게놈 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22256104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20000052796(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 벤슨 로버트 에이치., 휴먼 게놈 사이언시즈, 인코포레이티드 filed Critical 벤슨 로버트 에이치.
Publication of KR20000052796A publication Critical patent/KR20000052796A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019990703614A 1996-10-25 1996-10-25 뉴트로킨 알파 Ceased KR20000052796A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/017957 WO1998018921A1 (en) 1996-10-25 1996-10-25 NEUTROKINE $g(a)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7019418A Division KR20050004269A (ko) 1996-10-25 1996-10-25 뉴트로킨 알파

Publications (1)

Publication Number Publication Date
KR20000052796A true KR20000052796A (ko) 2000-08-25

Family

ID=22256104

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019990703614A Ceased KR20000052796A (ko) 1996-10-25 1996-10-25 뉴트로킨 알파
KR10-2004-7019418A Ceased KR20050004269A (ko) 1996-10-25 1996-10-25 뉴트로킨 알파

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2004-7019418A Ceased KR20050004269A (ko) 1996-10-25 1996-10-25 뉴트로킨 알파

Country Status (14)

Country Link
EP (3) EP1577391A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001503263A (cg-RX-API-DMAC7.html)
KR (2) KR20000052796A (cg-RX-API-DMAC7.html)
CN (1) CN1539970A (cg-RX-API-DMAC7.html)
AT (1) ATE302272T1 (cg-RX-API-DMAC7.html)
AU (1) AU731553B2 (cg-RX-API-DMAC7.html)
BR (1) BR9612752A (cg-RX-API-DMAC7.html)
CA (2) CA2266439C (cg-RX-API-DMAC7.html)
DE (1) DE69635088T3 (cg-RX-API-DMAC7.html)
DK (1) DK0939804T4 (cg-RX-API-DMAC7.html)
ES (1) ES2248823T5 (cg-RX-API-DMAC7.html)
NZ (1) NZ334309A (cg-RX-API-DMAC7.html)
PT (1) PT939804E (cg-RX-API-DMAC7.html)
WO (1) WO1998018921A1 (cg-RX-API-DMAC7.html)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
EP1012292A1 (en) * 1997-06-06 2000-06-28 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9376498A (en) * 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
BR9812433A (pt) * 1997-09-12 2000-09-26 Biogen Inc Kay- uma proteìna do sistema de imunização
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DE60043626D1 (de) * 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
ATE515267T1 (de) * 1999-01-25 2011-07-15 Biogen Idec Inc Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
CN100439499C (zh) * 1999-02-23 2008-12-03 人体基因组科学有限公司 Neutrokine-α和Neutrokine-α剪接变体
WO2000050597A2 (en) * 1999-02-23 2000-08-31 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) * 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CA2377585A1 (en) 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
EP1666052B1 (en) 2000-02-16 2011-06-08 Genentech, Inc. Anti-APRIL monoclonal antibody and its use for the treatment of an immune related disease or cancer
US6969519B2 (en) 2000-03-10 2005-11-29 Human Genome Sciences, Inc. Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
US6774106B2 (en) 2000-05-12 2004-08-10 Amgen Inc. Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3 and TACI
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
EP2014303A2 (en) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
CA2419661A1 (en) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2004533997A (ja) 2001-02-20 2004-11-11 ザイモジェネティクス，インコーポレイティド Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
EP1921088B1 (en) 2001-05-11 2014-10-08 Amgen Inc. Peptides and related molecules that bind to tall-1
MEP21708A (en) 2001-05-24 2010-06-10 Zymogenetics Inc Taci-immunoglobulin fusion proteins
ES2437992T3 (es) 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
ATE433996T1 (de) 2001-07-03 2009-07-15 Genentech Inc Humane dr4-antikörper und deren anwendungen
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
AU2002351495A1 (en) * 2001-10-17 2003-04-28 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
CA2489348A1 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
AU2003299819A1 (en) * 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
WO2005005462A2 (en) 2003-06-05 2005-01-20 Genentech, Inc. Blys antagonists and uses thereof
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
US8168445B2 (en) 2004-07-02 2012-05-01 Bio-Layer Pty Limited Use of metal complexes
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
MX2007001468A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
ATE535611T1 (de) 2004-09-15 2011-12-15 Kowa Co Verfahren zum screening des baff-suppressors oder inhibitors
US20060110387A1 (en) 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
UA93516C2 (ru) 2005-08-09 2011-02-25 Займоджинетикс, Инк. Способы лечения b-клеточных злокачественных образований c помощью слитой молекулы taci-ig
ES2376479T3 (es) 2005-08-16 2012-03-14 Genentech, Inc. Sensibilidad apoptótica a apo2l/trail mediante el ensayo de expresión de galnac-t14 en células y tejidos.
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AR060935A1 (es) 2006-05-15 2008-07-23 Ares Trading Sa Metodos para tratar enfermedades autoinmunes utilizando una molecula de fusion taci- ig
MX2011003039A (es) 2008-09-26 2011-08-15 Tocagen Inc Vectores de terapia genica y citosina deaminasas.
EA201190025A1 (ru) 2008-11-25 2012-12-28 Байоджен Айдек Ма Инк. ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20120104517A (ko) 2009-09-03 2012-09-21 제넨테크, 인크. 류마티스 관절염의 치료, 진단 및 모니터링 방법
CN103874707B (zh) 2010-11-19 2017-04-19 卫材R&D管理有限公司 中和抗‑ccl20抗体
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
DE102014018663A1 (de) 2014-12-13 2015-03-05 Heinz Kiefer Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
MX2023013114A (es) 2021-05-07 2023-11-17 Alpine Immune Sciences Inc Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc.
CN113238061B (zh) * 2021-07-09 2021-10-01 中南大学湘雅医院 以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
IL319997A (en) 2022-10-04 2025-06-01 Alpine Immune Sciences Inc Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
CN119799684A (zh) * 2024-12-27 2025-04-11 深圳先进技术研究院 一种靶向无害梭菌的抗菌蛋白及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4433092A (en) 1981-03-09 1984-02-21 Champion Spark Plug Company Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
ATE114673T1 (de) 1985-08-16 1994-12-15 Univ Rockefeller Modulator der anabolischen aktivität und seine verwendungen.
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5075236A (en) 1987-04-24 1991-12-24 Teijin Limited Method of detecting kawasaki disease using anti-tumor necrosis antibody
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures

Also Published As

Publication number Publication date
AU7674596A (en) 1998-05-22
AU731553B2 (en) 2001-04-05
CA2266439C (en) 2009-06-16
CN1539970A (zh) 2004-10-27
DK0939804T4 (da) 2011-07-18
EP2230307A1 (en) 2010-09-22
EP0939804A1 (en) 1999-09-08
CA2266439A1 (en) 1998-05-07
ES2248823T3 (es) 2006-03-16
KR20050004269A (ko) 2005-01-12
DE69635088T2 (de) 2006-06-14
CA2665133A1 (en) 1998-05-07
DK0939804T3 (da) 2005-12-19
ES2248823T5 (es) 2011-11-03
BR9612752A (pt) 2000-01-18
DE69635088T3 (de) 2012-01-26
EP0939804B1 (en) 2005-08-17
EP1577391A1 (en) 2005-09-21
PT939804E (pt) 2005-11-30
EP0939804B2 (en) 2011-06-15
JP2001503263A (ja) 2001-03-13
WO1998018921A1 (en) 1998-05-07
ATE302272T1 (de) 2005-09-15
DE69635088D1 (de) 2005-09-22
NZ334309A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
EP0939804B2 (en) NEUTROKINE alpha
US6689579B1 (en) Polynucleotides encoding neutrokine-α
KR100497017B1 (ko) 고사유도분자ii
US6635443B1 (en) Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
JP2001510035A (ja) インターロイキン−２０
KR20010103580A (ko) 인터루킨 17-유사 수용체 단백질
US20080317756A1 (en) Antibodies to Chemokine Alpha-5
US20020099198A1 (en) Human endokine alpha
JP2001500724A (ja) Ｔ１レセプター様リガンドｉｉ
JP2001513641A (ja) Ｔ１／ｓｔ２−レセプターリガンド▲ｉｉｉ▼
AU779750B2 (en) Neutrokine alpha
US8110659B1 (en) Human tumor necrosis factor receptor-like genes
HK1081233A (en) Neutrokine alpha
HK1148308A (en) Neutrokine alpha
US20030175894A1 (en) Chemokine alpha-6
JP2004129667A (ja) ニュートロカインα
HK1111195A (en) NEUTROKINE α
JP2009136294A (ja) ニュートロカインα
MXPA99002973A (en) NEUTROKINE&agr;
JP2012044999A (ja) ニュートロカインα
US20040132987A1 (en) Connective tissue growth factor-3
JP2007222174A (ja) ニュートロカインα
JP2004041216A (ja) ヒトエンドカインα

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990424

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20011025

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040119

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20040827

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20041129

PJ0201 Trial against decision of rejection

Patent event date: 20041129

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20040827

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20050513

Appeal identifier: 2004101005608

Request date: 20041129

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20041129

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20041129

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20040623

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20011025

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20050128

J801 Dismissal of trial

Free format text: REJECTION OF TRIAL FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20041129

Effective date: 20050513

PJ0801 Rejection of trial

Patent event date: 20050513

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20050513

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2004101005608

Request date: 20041129